Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 43, 2016, Pages 69267-69275

  Lee, Seung Eun ^a   Chang, Seong Hwan ^b   Kim, Wook Youn ^a   Lim, So Dug ^a   Kim, Wan Seop ^a   Hwang, Tea Sook ^a   Han, Hye Seung ^a  

^a Konkuk University Hospital   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

CTNNB1; Hepatocellular carcinoma; Intratumoral genetic heterogeneity; Pathology Section; TERT

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; TELOMERASE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; CONTROLLED STUDY; CTNNB1 GENE; FEMALE; GENE; GENE FUNCTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KOREAN (PEOPLE); LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY TUMOR; PROMOTER REGION; SEQUENCE ANALYSIS; SOMATIC MUTATION; TERT GENE; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; DNA MUTATIONAL ANALYSIS; ETHNOLOGY; GENETICS; LIVER TUMOR; MUTATION; PROCEDURES; SOUTH KOREA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; DNA MUTATIONAL ANALYSIS; FEMALE; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; REPUBLIC OF KOREA; TELOMERASE;

EID: 84994314579     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12121     Document Type: Article

References (30)

1. Cha C, Fong Y, Jarnagin WR, Blumgart LH and DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003; 197: 753-758.
2. Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, Taylor BR, Grant DR and Vollmer CM. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006; 202: 275-283.
3. Belghiti J, Panis Y, Farges O, Benhamou JP and Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991; 214: 114-117.
4. Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY and Chen SC. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg. 1994; 129: 738-742.
5. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati PL and Pigato P. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer. 1998; 82: 1028-1036.
6. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H, Yamamoto S, Shinbrot E, Hama N, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014; 46: 1267-1273.
7. Jhunjhunwala S, Jiang Z, Stawiski EW, Gnad F, Liu J, Mayba O, Du P, Diao J, Johnson S, Wong KF, Gao Z, Li Y, Wu TD, et al. Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol. 2014; 15: 436.
8. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C and Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013; 4: 2218.
9. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Jr., Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of selfrenewal. Proc Natl Acad Sci U S A. 2013; 110: 6021-6026.
10. Quaas A, Oldopp T, Tharun L, Klingenfeld C, Krech T, Sauter G and Grob TJ. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch. 2014; 465: 673-677.
11. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D and Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339: 959-961.
12. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA and Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013; 98: E1562-1566.
13. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K and Kumar R. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013; 110: 17426-17431.
14. Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A and Kumar R. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015; 17: 45-52.
15. Shay JW and Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33: 787-791.
16. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A and Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1998; 95: 8847-8851.
17. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G and Ohgaki H. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol. 1999; 155: 1795-1801.
18. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P and Perret C. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007; 26: 774-780.
19. Nault JC, Bioulac-Sage P and Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology. 2013; 144: 888-902.
20. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012; 44: 765-769.
21. Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D and Brechot C. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene. 2003; 22: 3911-3916.
22. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang L, Zhou S, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 2011; 43: 828-829.
23. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, et al. Integrated analysis of somatic mutations and focal copynumber changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44: 694-698.
24. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012; 44: 760-764.
25. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M and Zucman-Rossi J. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014; 60: 1983-1992.
26. Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl. 2004; 10: S3-8.
27. Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY and Park CK. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 2005; 25: 70-76.
28. Friemel J, Rechsteiner M, Frick L, Bohm F, Struckmann K, Egger M, Moch H, Heikenwalder M and Weber A. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res. 2015; 21: 1951-1961.
29. Edmondson HA and Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7: 462-503.
30. Oh SY and Lee HT. Efficiency of EGFR mutation analysis for small microdissected cytological specimens using multitech DNA extraction solution. Cancer Cytopathol. 2015; 123: 401-412.